Your browser doesn't support javascript.
loading
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Wildschut, Mattheus H E; Mena, Julien; Dördelmann, Cyril; van Oostrum, Marc; Hale, Benjamin D; Settelmeier, Jens; Festl, Yasmin; Lysenko, Veronika; Schürch, Patrick M; Ring, Alexander; Severin, Yannik; Bader, Michael S; Pedrioli, Patrick G A; Goetze, Sandra; van Drogen, Audrey; Balabanov, Stefan; Skoda, Radek C; Lopes, Massimo; Wollscheid, Bernd; Theocharides, Alexandre P A; Snijder, Berend.
Afiliação
  • Wildschut MHE; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.
  • Mena J; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Dördelmann C; Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
  • van Oostrum M; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.
  • Hale BD; Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.
  • Settelmeier J; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Festl Y; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.
  • Lysenko V; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Schürch PM; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Ring A; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.
  • Severin Y; Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
  • Bader MS; Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
  • Pedrioli PGA; Department of Medical Oncology and Hematology, Division of Hematology, University Hospital Zurich, Zurich, Switzerland.
  • Goetze S; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.
  • van Drogen A; Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Balabanov S; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Skoda RC; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Lopes M; ETH PHRT Swiss Multi-Omics Center (SMOC), Zurich, Switzerland.
  • Wollscheid B; Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Theocharides APA; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
  • Snijder B; ETH PHRT Swiss Multi-Omics Center (SMOC), Zurich, Switzerland.
Nat Commun ; 14(1): 6414, 2023 10 12.
Article em En | MEDLINE | ID: mdl-37828014
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mielofibrose Primária / Transtornos Mieloproliferativos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mielofibrose Primária / Transtornos Mieloproliferativos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article